Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386878512> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W4386878512 abstract "Biphasic insulin aspart 30 is a premixed formulation containing a soluble fraction of insulin aspart (30%) and a protamine-crystallized fraction (70%) that was developed to combine the rapid-acting and prolonged advantages of commercially available insulins. The aim of this bioequivalence study was to compare the pharmacokinetics (PKs) of GP-bi-asp and Novo-bi-asp, and evaluate the pharmacodynamic (PD) properties as well as the safety of these drugs in the hyperinsulinemic euglycemic clamp (HEC) procedure. This was a phase 1, randomized, double-blind, 2-sequence, 2-period crossover study. Thirty-four male volunteers who met the inclusion criteria underwent the HEC procedure following a single subcutaneous injection of 0.4 IU/kg of either GP-bi-asp or Novo-bi-asp in the abdomen. After the treatment, the subjects' plasma glucose levels were monitored for 24 hours and the glucose infusion rate (GIR) was adjusted to maintain the target blood glucose level. The PD parameters were calculated using GIR values. Insulin aspart concentrations were measured in blood plasma using validated ELISA assays to evaluate the PK parameters of the investigated drugs. The 90% confidence intervals for the geometric mean ratios of PK (Cins and AUCins-T ) parameters of Gp-bi-asp and Novo-bi-asp were close to 100% and within the 80%-125% limits for establishing bioequivalence. The safety profiles of both drugs were also comparable." @default.
- W4386878512 created "2023-09-21" @default.
- W4386878512 creator A5006343223 @default.
- W4386878512 creator A5009071256 @default.
- W4386878512 creator A5009464284 @default.
- W4386878512 creator A5022584888 @default.
- W4386878512 creator A5027769926 @default.
- W4386878512 creator A5043877274 @default.
- W4386878512 creator A5045551922 @default.
- W4386878512 creator A5069309869 @default.
- W4386878512 creator A5075509540 @default.
- W4386878512 creator A5092906441 @default.
- W4386878512 date "2023-09-20" @default.
- W4386878512 modified "2023-09-27" @default.
- W4386878512 title "Bioequivalence of Reference and Biosimilar Preparations of Premixed Biphasic Insulin Aspart: A Comparative Clamp Study" @default.
- W4386878512 cites W2047722718 @default.
- W4386878512 cites W2053398017 @default.
- W4386878512 cites W2120352437 @default.
- W4386878512 cites W2134664501 @default.
- W4386878512 cites W2141124195 @default.
- W4386878512 cites W2463897233 @default.
- W4386878512 cites W4214619570 @default.
- W4386878512 cites W4241935632 @default.
- W4386878512 doi "https://doi.org/10.1002/cpdd.1333" @default.
- W4386878512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37728234" @default.
- W4386878512 hasPublicationYear "2023" @default.
- W4386878512 type Work @default.
- W4386878512 citedByCount "0" @default.
- W4386878512 crossrefType "journal-article" @default.
- W4386878512 hasAuthorship W4386878512A5006343223 @default.
- W4386878512 hasAuthorship W4386878512A5009071256 @default.
- W4386878512 hasAuthorship W4386878512A5009464284 @default.
- W4386878512 hasAuthorship W4386878512A5022584888 @default.
- W4386878512 hasAuthorship W4386878512A5027769926 @default.
- W4386878512 hasAuthorship W4386878512A5043877274 @default.
- W4386878512 hasAuthorship W4386878512A5045551922 @default.
- W4386878512 hasAuthorship W4386878512A5069309869 @default.
- W4386878512 hasAuthorship W4386878512A5075509540 @default.
- W4386878512 hasAuthorship W4386878512A5092906441 @default.
- W4386878512 hasBestOaLocation W43868785121 @default.
- W4386878512 hasConcept C111113717 @default.
- W4386878512 hasConcept C112705442 @default.
- W4386878512 hasConcept C126322002 @default.
- W4386878512 hasConcept C126894567 @default.
- W4386878512 hasConcept C142724271 @default.
- W4386878512 hasConcept C204787440 @default.
- W4386878512 hasConcept C27081682 @default.
- W4386878512 hasConcept C2779306644 @default.
- W4386878512 hasConcept C2779908123 @default.
- W4386878512 hasConcept C2780668416 @default.
- W4386878512 hasConcept C42404028 @default.
- W4386878512 hasConcept C44249647 @default.
- W4386878512 hasConcept C71924100 @default.
- W4386878512 hasConcept C87813604 @default.
- W4386878512 hasConcept C98274493 @default.
- W4386878512 hasConceptScore W4386878512C111113717 @default.
- W4386878512 hasConceptScore W4386878512C112705442 @default.
- W4386878512 hasConceptScore W4386878512C126322002 @default.
- W4386878512 hasConceptScore W4386878512C126894567 @default.
- W4386878512 hasConceptScore W4386878512C142724271 @default.
- W4386878512 hasConceptScore W4386878512C204787440 @default.
- W4386878512 hasConceptScore W4386878512C27081682 @default.
- W4386878512 hasConceptScore W4386878512C2779306644 @default.
- W4386878512 hasConceptScore W4386878512C2779908123 @default.
- W4386878512 hasConceptScore W4386878512C2780668416 @default.
- W4386878512 hasConceptScore W4386878512C42404028 @default.
- W4386878512 hasConceptScore W4386878512C44249647 @default.
- W4386878512 hasConceptScore W4386878512C71924100 @default.
- W4386878512 hasConceptScore W4386878512C87813604 @default.
- W4386878512 hasConceptScore W4386878512C98274493 @default.
- W4386878512 hasLocation W43868785121 @default.
- W4386878512 hasLocation W43868785122 @default.
- W4386878512 hasOpenAccess W4386878512 @default.
- W4386878512 hasPrimaryLocation W43868785121 @default.
- W4386878512 hasRelatedWork W1971830765 @default.
- W4386878512 hasRelatedWork W2055974197 @default.
- W4386878512 hasRelatedWork W2081239230 @default.
- W4386878512 hasRelatedWork W2145754676 @default.
- W4386878512 hasRelatedWork W2399977644 @default.
- W4386878512 hasRelatedWork W2520432931 @default.
- W4386878512 hasRelatedWork W2531277573 @default.
- W4386878512 hasRelatedWork W3034425054 @default.
- W4386878512 hasRelatedWork W3145656073 @default.
- W4386878512 hasRelatedWork W3158663263 @default.
- W4386878512 isParatext "false" @default.
- W4386878512 isRetracted "false" @default.
- W4386878512 workType "article" @default.